Nucleix

Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection, at a time when intervention can bring the greatest impact for patients. Prior to joining Nucleix, Todd was the chief financial officer of Astute Medical, which was acquired in 2018 by bioMerieux, a multinational biotechnology company headquartered in France. Prior to joining Nucleix, Eli was Managing Director of Aurum Ventures, a healthcare-focused VC, serving on the Boards of its 10 portfolio companies, across different healthcare segments. Prior to Nucleix, Aharona served as Medical Manager at Roche Pharmaceutical Israel, Medical Director at AstraZeneca Israel, Senior Global Product Manager in Philips Healthcare and VP Oncology at Insightec. As co-founder of Nucleix, Danny brings extensive experience and know-how in molecular biology, cancer genetics, and DNA biochemistry. Prior to Nucleix, Radha served as Director of Clinical Operations and Clinical Development at Karius driving the clinical validity, utility and publication strategy for the Karius® Test (liquid biopsy for infectious diseases) in immunocompromised patients suspected with pneumonia. Nucleix R&D has the capabilities and experience to develop additional liquid biopsy assays for other types of cancer. We are working with leading medical centers, organizations and laboratories worldwide.